These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 18256859)
1. Established and potential therapeutic applications of octreotide in palliative care. Prommer EE Support Care Cancer; 2008 Oct; 16(10):1117-23. PubMed ID: 18256859 [TBL] [Abstract][Full Text] [Related]
3. The use of octreotide to manage symptoms of bronchorrhea: a case report. Pahuja M; Shepherd RW; Lyckholm LJ J Pain Symptom Manage; 2014 Apr; 47(4):814-8. PubMed ID: 24035070 [TBL] [Abstract][Full Text] [Related]
4. The palliative effects of octreotide in cancer patients. Dean A Chemotherapy; 2001; 47 Suppl 2():54-61. PubMed ID: 11275702 [TBL] [Abstract][Full Text] [Related]
5. [The therapeutic applications of octreotide]. Carrera-Hueso FJ; Carrera-Hueso JA; Llorente I Med Clin (Barc); 1996 Apr; 106(13):505-16. PubMed ID: 8992134 [No Abstract] [Full Text] [Related]
6. Long-term follow-up of two patients with metastatic neuroendocrine tumours treated with octreotide. van de Loosdrecht AA; van Bodegraven AA; Sepers JM; Sindram JW Neth J Med; 1998 Sep; 53(3):118-23. PubMed ID: 9803143 [TBL] [Abstract][Full Text] [Related]
7. The palliative effects of octreotide in malignant disease. Dean A; Bridge D; Lickiss JN Ann Acad Med Singap; 1994 Mar; 23(2):212-5. PubMed ID: 7521613 [TBL] [Abstract][Full Text] [Related]
8. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G Oncology; 2001; 60(2):141-5. PubMed ID: 11244329 [TBL] [Abstract][Full Text] [Related]
9. Octreotide. Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003 [No Abstract] [Full Text] [Related]
15. Neuroendocrine tumours - Medical therapy: Biological. Rinke A; Krug S Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):79-91. PubMed ID: 26971845 [TBL] [Abstract][Full Text] [Related]
16. Octreotide LAR in carcinoid: how to dose? Yao JC; Kvols LK Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562 [No Abstract] [Full Text] [Related]
17. Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire. Pistevou-Gombaki K; Eleftheriadis N; Plataniotis GA; Sofroniadis I; Kouloulias VE Palliat Med; 2003 Apr; 17(3):257-62. PubMed ID: 12725479 [TBL] [Abstract][Full Text] [Related]